The need for expedited delivery prior to the second dose of late preterm corticosteroids (LPCS) is common in clinical practice. Our objective was to estimate the rate of neonatal respiratory support, stillbirth or death 72h after delivery in women receiving a single vs two doses of LPCS. STUDY DESIGN: Secondary analysis of a multicenter trial of LPCS for prevention of neonatal respiratory morbidity and mortality. All women intended for LPCS and received either 1 or 2 doses at 34 0/7 to 36 6/7 wk were included for analysis. Major anomalies were excluded. Primary outcome was rate of neonatal respiratory support (CPAP or high-flow nasal cannula for at least 2 consecutive hrs, supplemental oxygen with FiO2 at least 0.3 for at least 4 continuous hrs, ECMO, or mechanical ventilation), stillbirth or death 72h after delivery. Secondary outcome was rate of respiratory distress syndrome (RDS). Multivariate logistic regression was performed for confounder control. Adjusted odds ratios (aOR) and 95% confidence intervals (CI) were reported for outcomes of interest. RESULTS: Of 1416 women meeting inclusion criteria, 561 (40%) received only a single dose of LPCS. Relevant baseline characteristics are shown in Table 1 . Latency from randomization to delivery among those who received a single dose was shorter (26AE84 vs 152AE175 hrs). After logistic regression, the rate of neonatal respiratory support, stillbirth or death 72h after delivery was similar between those receiving 1 vs 2 doses (15 vs 10 %, aOR 1.41, 95% CI 0.96-2.08). Conversely, a single dose was not associated with lower rate of RDS (8 vs 4%, aOR 1.98, 95% CI 1.17-3.36). Other neonatal outcomes were similar between groups (Table 2) . CONCLUSION: In women at risk for late preterm delivery, administration of single vs two doses of LPCS is associated with similar rates of neonatal respiratory support, stillbirth or neonatal death 72h after delivery; without decreasing the risk for RDS. This finding is relevant in appropriately selected women who require prompt delivery. OBJECTIVE: Cervical length (CL) measurement is the best clinical predictor of preterm birth (PTB) but overall has only modest accuracy. Only one-third of short CL patients deliver prematurely. Our objective was to use metabolomics-generated biomarkers to predict PTB in asymptomatic cases with significant CL shortening. STUDY DESIGN: This is a prospective study of asymptomatic short CL cases (<25 mm) in singleton pregnancies. Extensive sonographic (CL, funneling, sludge), clinical, demographic, obstetric and historical data were obtained for each patient. Targeted analysis of maternal serum using two metabolomic platforms: Liquid chromatography e mass spectrometry -mass spectrometry (LC-MS-MS)) and proton-based Nuclear Magnetic Resonance ( 1 H-NMR) were performed. The primary outcomes assessed were moderate (<34 weeks) and severe (<28 weeks) PTB. Logistic regression was used to generate predictive algorithms and areas under the ROC curve [AUC (95% CI)], sensitivity, and specificity for predicting PTB calculated. The predictive performance of metabolites alone and metabolites combined with CL, clinical /demographic markers (including race, parity and history of prior PTB) for PTB prediction were determined. RESULTS: There were a total of 39 cases of asymptomatic short CL of which 16/39 (41.0%) delivered at <34 weeks and 13/39 (33.3%) of patients delivered at <28 weeks. There were no significant differences in maternal race (p¼0.75) or prior PTB [4/16 (25%) vs 8/23 (34.8%) p¼0.73] respectively between the < 34 and ! 34 groups with shorter CL in the former: mean (AESD) CL [0.75 (AE2.18) mm vs 9.96 (AE7.29) mm; p < 0.001]. Metabolomics markers ( primarily t4 -OH proline, sphingomyelin C22.3 and serotonin) were important biomarkers. Results for PTB < 34 weeks are shown in Table 1 . Adding CL, and clinical demographic data further improved performance over metabolomics data alone. Excellent predictive accuracy for PTB < 28 weeks using the metabolites, Cl and clinical markers (Table 2) . Traditional clinical predictors such as race and prior PTB did not further improve performance. CONCLUSION: We identifiedmetabolomic markers with excellent predictive accuracy for moderate and severe PTB prediction in ajog.org
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